Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease

Bone Marrow Transplantation volume 46, pages 27–33 (2011)Cite this article

Subjects

Abstract

Busulfan influences engraftment and toxicities during hematopoietic stem cell transplantation (HSCT). We report our single-institution experience of targeted busulfan therapy for myeloablative, matched sibling donor (MSD) HSCT for sickle cell disease (SCD) and assess the relationships of busulfan levels to engraftment and toxicities. Twenty-seven patients with SCD underwent MSD HSCT from 1993 to 2007, 25 with busulfan measurements. The conditioning regimen was busulfan (initial dose 0.875 mg/kg for 16 doses), CY and antithymocyte globulin. Busulfan area under curve (AUC) was determined with the first dose, and dose adjustments were made to target the desired AUC range. Median AUC was 963 μmol min/L (range 780–1305 μmol min/L). Engraftment occurred in all cases: 21 (84%) full donor chimerism (>95% donor cells), 4 (16%) partial donor chimerism. Hepatic veno-occlusive disease (VOD) occurred in 8 (32%) patients. Lower AUC was seen with partial donor chimerism (862±73 μmol min/L) versus full donor chimerism (AUC 1018±122 μmol min/L) (P=0.022). VOD was not associated with busulfan AUC (P=0.153). Of 25 patients, 24 survived with median follow-up of 4.9 years. Our experience shows that targeting busulfan AUC above the range used in previous multicenter trials appears safe and may contribute to sustained engraftment in SCD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Tutschka PJ, Santon GW . Bone marrow transplantation in the busulfin-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients. Transplantation 1977; 24: 52–62.

    Article  CAS  Google Scholar 

  2. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31–42.

    CAS  PubMed  Google Scholar 

  3. Chandy M, Balasubramanian P, Ramachandran SV, Mathews V, George B, Dennison D et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia—the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 2005; 36: 839–845.

    Article  CAS  Google Scholar 

  4. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203–6207.

    CAS  PubMed  Google Scholar 

  5. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55–61.

    Article  CAS  Google Scholar 

  6. Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G . High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997; 20: 909–913.

    Article  CAS  Google Scholar 

  7. Walters MC, Patience M, Leisenring W, Rogers ZR, Aquino VM, Buchanan GR et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001; 7: 665–673.

    Article  CAS  Google Scholar 

  8. McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 167–173.

    Article  CAS  Google Scholar 

  9. Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 307–314.

    Article  CAS  Google Scholar 

  10. Zwaveling J, Bredius RG, Cremers SC, Ball LM, Lankester AC, Teepe-Twiss IM et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005; 35: 17–23.

    Article  CAS  Google Scholar 

  11. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477–485.

    Article  CAS  Google Scholar 

  12. Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001; 28: 1013–1018.

    Article  CAS  Google Scholar 

  13. Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000; 95: 1918–1924.

    CAS  PubMed  Google Scholar 

  14. Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F et al. Pulmonary, gonadal and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant 2010; 16: 263–272.

    Article  Google Scholar 

  15. Walters MC, Patience M, Leisenring W, Eckman JR, Scott JP, Mentzer WC et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996; 335: 369–376.

    Article  CAS  Google Scholar 

  16. Grochow LB . Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20 (4 Suppl 4): 18–25; quiz 26.

    CAS  PubMed  Google Scholar 

  17. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

    Article  CAS  Google Scholar 

  18. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED . Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116–122.

    Article  CAS  Google Scholar 

  19. Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110: 2749–2756.

    Article  CAS  Google Scholar 

  20. Andreani M, Nesci S, Lucarelli G, Tonucci P, Rapa S, Angelucci E et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000; 25: 401–404.

    Article  CAS  Google Scholar 

  21. Amrolia PJ, Vulliamy T, Vassiliou G, Lawson S, Bryon J, Kaeda J et al. Analysis of chimerism in thalassaemic children undergoing stem cell transplantation. Br J Haematol 2001; 114: 219–225.

    Article  CAS  Google Scholar 

  22. Krishnamurti L, Kharbanda S, Biernacki MA, Zhang W, Baker KS, Wagner JE et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2008; 14: 1270–1278.

    Article  Google Scholar 

  23. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322: 417–421.

    Article  CAS  Google Scholar 

  24. Bhatia M, Walters MC . Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplant 2008; 41: 109–117.

    Article  CAS  Google Scholar 

  25. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225–230.

    CAS  PubMed  Google Scholar 

  26. Grochow LB, Krivit W, Whitley CB, Blazar B . Busulfan disposition in children. Blood 1990; 75: 1723–1727.

    CAS  PubMed  Google Scholar 

  27. Yeager AM, Wagner Jr JE, Graham ML, Jones RJ, Santos GW, Grochow LB . Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425–2428.

    CAS  PubMed  Google Scholar 

  28. McPherson ME, Anderson AR, Haight AE, Jessup P, Castillejo MI, Hillyer CD et al. Transfusion management of sickle cell patients during bone marrow transplantation with matched sibling donor. Transfusion 2009; 49: 1977–1986.

    Article  Google Scholar 

  29. Eggleston B, Patience M, Edwards S, Adamkiewicz T, Buchanan GR, Davies SC et al. Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia. Br J Haematol 2007; 136: 673–676.

    Article  CAS  Google Scholar 

  30. Rozman C, Carreras E, Qian C, Gale RP, Bortin MM, Rowlings PA et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 1996; 17: 75–80.

    CAS  PubMed  Google Scholar 

  31. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M . Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181–186.

    Article  CAS  Google Scholar 

  32. Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002; 8: 493–500.

    Article  CAS  Google Scholar 

  33. Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005–3020.

    CAS  PubMed  Google Scholar 

  34. Ciurea SO, Andersson BS . Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 523–536.

    Article  CAS  Google Scholar 

  35. Morris CR . Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program 2008; 2008: 177–185.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA

    M E McPherson, A E Haight, J Horan & K-Y Chiang

  2. Pediatric Hematology/Oncology/Bone Marrow Transplantation, Emory University School of Medicine, Atlanta, GA, USA

    M E McPherson, E Olson, A E Haight, J Horan & K-Y Chiang

  3. Winship Cancer Institute, Emory Healthcare, Atlanta, GA, USA

    D Hutcherson

Authors
  1. M E McPherson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Hutcherson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Olson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A E Haight
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Horan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K-Y Chiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M E McPherson.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McPherson, M., Hutcherson, D., Olson, E. et al. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant 46, 27–33 (2011). https://doi.org/10.1038/bmt.2010.60

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.60

Keywords

This article is cited by

Search

Advanced search

Quick links